Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: A pilot study

Rheumatology International

Volumn 25, Issue 4, 2005, Pages 296-300

  Ringe, J D ^a   Dorst, A ^a   Faber, H ^a   Kipshoven, C ^b   Rovati, L C ^c   Setnikar, I ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Opfermann Arzneimittel GmbH   (Germany)

^c Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETIDRONIC ACID; FLUOROPHOSPHATE; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; GASTROINTESTINAL TOXICITY; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA FRACTURE;

AGED; BONE AND BONES; BONE DENSITY; CALCANEUS; CALCIUM; DENSITOMETRY, X-RAY; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; FLUORIDES; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN; PHOSPHATES; PILOT PROJECTS; RANGE OF MOTION, ARTICULAR; SPINAL FRACTURES; TREATMENT OUTCOME; VITAMIN D;

EID: 20044389711     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0570-x     Document Type: Article

References (22)

1. Dempster DW (2002) The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 13:349-352
2. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
3. Mertz W (1981) The essential trace elements. Science 213:1332-1338
4. Ringe JD (2004) Fluoride and bone health. In: Holick MF, Dawson-Hughes B (eds) Nutrition, bone health. Humana, Totowa NJ, pp 345-362
5. Ringe JD (2002) Fluoride in osteoporosis. In: Bilezekian JP et al (eds) Principles of bone biology, 2nd edn, vol 2. Academic, New York, pp 1387-1399
6. Müller P, Schmid K, Warneke G, Setnikar I, Simon B (1992) Sodium fluoride-induced gastric mucosal lesions: comparison with sodium monofluorophosphate. Z Gastroenterol 30:252-254
7. Setnikar I, Maurer H (1990) Bioequivalence of sodium monofluorophosphate with sodium fluoride and compatibility with calcium. Arzneimittelforschung 40:994-999
8. Warneke G, Setnikar I (1993) Effects of meal on the pharmacokinetics of fluoride from oral monofluorophosphate. Arzneimittelforschung 43:590-595
9. Gambacciani M, Spinetti A, Cappagli B, Ciaponi M, Gallo R, Rovati LC, Genazzani AR (1995) Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss. Eur Menopause J 2:16-20
10. Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 84:3013-3020
11. Ringe JD, Setnikar I (2002) Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis: an open-label pilot efficacy and safety study. Rheumatol Int 22:27-32
12. Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741-749
13. Lems WF, Jacobs JWG, Bijlsma WJ, van Veen GJM, Houben HHML, Haanen HCM, Gerrits MI, van Rijn HJM (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheum Dis 56:357-363
14. Ringe JD, Rovati L (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252-255
15. Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N (2003) Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14:500-506
16. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxseri ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
17. Ringe JD, Kipshoven C, Cöster A, Umbach R (1999) Therapy of established post-menopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171-178
18. Kanis JA (1994) Treatment of generalized osteoporosis with inhibitors of bone resorption. In: Kanis JA (ed) Osteoporosis. Blackwell, London, pp 168-195
19. Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline activity of bone-forming cells. Science 222:330-332
20. Pak CY, Zerwekh JE, Antich P (1995) Anabolic effects of fluoride on bone. Trends Endocrinol Metab 6:229-234
21. Caverzasio J, Palmer G, Bonjour JP (1998) Fluoride: mode of action. Bone 22:585-589
22. Banse X, Devogelaer JP, Delloye C, Lafosse A, Holmyard D, Grynpas M (2003) Irreversible perforations in vertebral trabeculae? J Bone Miner Res 18:1247-1253